Biogen Inc (BIIB)
230.70
+1.42 +0.62%
NASDAQ
May 20, 16:35
Delayed 2m
USD
View All Key Stats
BIIB Key Stats
| Income Statement | |
| Revenue (TTM) | 13.81B |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | 23.21 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | 4.667B |
| Profitability | |
| Gross Profit Margin (Quarterly) | 82.75% |
| Profit Margin (Quarterly) | 40.37% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield (TTM) | Upgrade |
| Price and Valuation | |
| Market Cap | 44.73B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio (TTM) | 3.367 |
| PE Ratio (TTM) | 9.940 |
| Price to Book Value | 3.234 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio (Quarterly) | Upgrade |
| Free Cash Flow (Quarterly) | 1.332B |
| Return on Equity (TTM) | Upgrade |
View All BIIB News
BIIB News
-
WireHeadlineTime (ET)
-
MT Newswires05/20 12:25
-
Yahoo05/20 11:27
-
SA Breaking News05/20 07:57
-
Yahoo05/20 07:40
-
Globe Newswire05/20 07:30
-
Yahoo05/17 17:17
-
Yahoo05/16 14:54
-
MT Newswires05/16 05:51
-
Yahoo05/16 05:00
-
MT Newswires05/15 08:10
View All Events
BIIB Events
| Date | Type | Description |
|---|---|---|
| 07/24/2019 08:00 EDT | Misc | Biogen Inc Second Quarter Earnings Conference Call in 2019 |
| 07/24/2019 | Earnings | Biogen Inc Second Quarter Earnings in 2019 Release |
| 04/24/2019 | Earnings | Biogen Inc First Quarter Earnings Results in 2019 |
| 04/24/2019 08:00 EDT | Misc | Biogen Inc First Quarter Earnings Conference Call in 2019 |
| 02/06/2019 | Misc | Biogen Inc Annual Report in 2018 |
| 01/29/2019 08:00 EST | Misc | Biogen Inc Fourth Quarter Earnings Conference Call in 2018 |
| 01/29/2019 | Earnings | Biogen Inc Fourth Quarter Earnings Results in 2018 |
| 10/23/2018 08:00 EDT | Misc | Biogen Inc Third Quarter Earnings Conference Call in 2018 |
| 10/23/2018 | Earnings | Biogen Inc Third Quarter Earnings Results in 2018 |
| 07/24/2018 08:00 EDT | Misc | Biogen Inc Second Quarter Earnings Conference Call in 2018 |
BIIB Fundamentals
Income Statement View Statement
BIIB Ratings
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
Advertisement
BIIB One Page Reports
- One Page Report Download
BIIB Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 230.70 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Edit
Profile
- URL: http://www.biogen.com
- Investor Relations URL: https://www.biogen.com/en_us/investors.html
- HQ State/Province: Massachusetts
- Sector: Healthcare
- Industry: Drug Manufacturers - Major
- Equity Style: Large Cap/Value
- Next Earnings Release: Jul. 24, 2019
- Last Earnings Release: Apr. 24, 2019
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
- Description: Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Tysabri and Tecfidera. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.
Excel Add-In Codes
- Name: =YCI("BIIB","name")
- Description: =YCI("BIIB","description")
- Sector: =YCI("BIIB","sector")
- Industry: =YCI("BIIB","industry")
- Est. Current Fiscal Year End: =YCI("BIIB","fye")
To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.
Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.
Other BIIB Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- BIIB Tweets Stocktwits
Advertisement
